Item 8.01 Other Events.

On January 13, 2021, SIGA Technologies, Inc. (the "Company") announced that the Public Health Agency of Canada (the "PHAC") has awarded a contract (the "Contract") to Meridian Medical Technologies, Inc., a Pfizer Company ("Meridian"), pursuant to which PHAC will purchase up to approximately $33 million of oral TPOXX® (tecovirimat) within five years. The Contract specifies firm commitments for the purchase of approximately $3.4 million of oral TPOXX by March 31, 2021 and a cumulative purchase of approximately $17.2 million of oral TPOXX by March 31, 2023. The remaining courses under the Contract are scheduled to be purchased after March 31, 2023 and are subject to option exercise by PHAC. The Contract award follows, but is separate and incremental to, the issuance in April, 2020 of a contract by the Canadian Department of National Defence for the delivery of up to approximately $14 million of oral TPOXX. The contract award was coordinated between the Company and Meridian under the international promotion agreement that was entered into between the Company and Meridian on June 3, 2019.

Item 9.01. Financial Statements and Exhibits.





(c) Exhibits



Exhibit No.      Description

  99.1           Press Release, dated January 13, 2021
104              Cover Page Interactive Data File (embedded within the Inline
                 XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses